SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa…
VANCOUVER, BC, April 15, 2025 /PRNewswire/ - A new U.S. Neurological Devices Market Report provides essential insights for CEOs, CFOs, product…
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April…
KENNEWICK, Wash., April 15, 2025 /PRNewswire/ -- Cadwell Industries, Inc., a global leader in neurodiagnostic, neuromonitoring, and sleep solutions, today…
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or…
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Google Cloud's commitment to AI-powered…
– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected…
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting…
HONOLULU, April 09, 2025 (GLOBE NEWSWIRE) -- Arialief is a premium dietary supplement specifically designed to target the root causes…
LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…
